Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial by Emary, Katherine R W et al.
Northumbria Research Link
Citation: Emary, Katherine R W, Golubchik, Tanya, Aley, Parvinder K, Ariani, Cristina V, Angus, Brian, 
Bibi, Sagida, Blane, Beth, Bonsall,  David, Cicconi, Paola, Charlton, Sue, Clutterbuck, Elizabeth A, 
Collins, Andrea M, Cox, Tony, Darton, Thomas C, Dold, Christina, Douglas, Alexander D, Duncan,  
Christopher J A, Ewer, Katie J, Flaxman, Amy L, Faust, Saul N, Ferreira, Daniela M, Feng, Shuo,  
Finn, Adam, Folegatti, Pedro M, Fuskova, Michelle, Galiza, Eva, Goodman, Anna L, Green, Catherine 
M, Green, Christopher A, Greenland, Melanie, Hallis, Bassam, Heath, Paul T, Hay, Jodie, Hill, Helen 
C,  Jenkin,  Daniel,  Kerridge,  Simon,  Lazarus,  Rajeka,  Libri,  Vincenzo,  Lillie,  Patrick  J,  Ludden, 
Catherine, Marchevsky,  Natalie G, Minassian, Angela M, McGregor, Alastair  C,  Mujadidi,  Yama F, 
Phillips, Daniel J, Plested, Emma, Pollock, Katrina M, Robinson, Hannah, Smith, Andrew, Song, Rinn, 
Snape, Matthew D, Sutherland, Rebecca K, Thomson, Emma C, Toshner, Mark, Turner, David P J, 
Vekemans,  Johan,  Villafana,  Tonya  L,  Williams,  Christopher  J,  Hill,  Adrian  V  S,  Lambe,  Teresa, 
Gilbert,  Sarah C, Voysey,  Merryn,  Ramasamy,  Maheshi  N,  Pollard,  Andrew J,  Bashton,  Matthew, 
Young, Greg, Nelson, Andrew and Smith, Darren (2021) Efficacy of ChAdOx1 nCoV-19 (AZD1222) 
vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a 




This  version  was  downloaded  from  Northumbria  Research  Link: 
http://nrl.northumbria.ac.uk/id/eprint/46048/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to access 
the University’s research output. Copyright © and moral rights for items on NRL are retained by the 
individual author(s) and/or other copyright owners.  Single copies of full items can be reproduced, 
displayed or performed, and given to third parties in any format or medium for personal research or 
study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, 
title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata 
page. The content must not be changed in any way. Full items must not be sold commercially in any  
format or medium without formal permission of the copyright holder.  The full policy is available online: 
http://nrl.northumbria.ac.uk/pol  i cies.html  
This  document  may differ  from the  final,  published version of  the research  and has been made 
available online in accordance with publisher policies. To read and/or cite from the published version 
of the research, please visit the publisher’s website (a subscription may be required.)
                        

Articles
www.thelancet.com   Vol 397   April 10, 2021 1351
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against 
SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): 
an exploratory analysis of a randomised controlled trial
Katherine R W Emary*, Tanya Golubchik*, Parvinder K Aley, Cristina V Ariani, Brian Angus, Sagida Bibi, Beth Blane, David Bonsall, Paola Cicconi, 
Sue Charlton, Elizabeth A Clutterbuck, Andrea M Collins, Tony Cox, Thomas C Darton, Christina Dold, Alexander D Douglas, 
Christopher J A Duncan, Katie J Ewer, Amy L Flaxman, Saul N Faust, Daniela M Ferreira, Shuo Feng, Adam Finn, Pedro M Folegatti, 
Michelle Fuskova, Eva Galiza, Anna L Goodman, Catherine M Green, Christopher A Green, Melanie Greenland, Bassam Hallis, Paul T Heath, 
Jodie Hay, Helen C Hill, Daniel Jenkin, Simon Kerridge, Rajeka Lazarus, Vincenzo Libri, Patrick J Lillie, Catherine Ludden, Natalie G Marchevsky, 
Angela M Minassian, Alastair C McGregor, Yama F Mujadidi, Daniel J Phillips, Emma Plested, Katrina M Pollock, Hannah Robinson, Andrew Smith, 
Rinn Song, Matthew D Snape, Rebecca K Sutherland, Emma C Thomson, Mark Toshner, David P J Turner, Johan Vekemans, Tonya L Villafana, 
Christopher J Williams, Adrian V S Hill*, Teresa Lambe*, Sarah C Gilbert*, Merryn Voysey*, Maheshi N Ramasamy*, Andrew J Pollard*, on behalf of 
the COVID-19 Genomics UK consortium†, the AMPHEUS Project†, and the Oxford COVID-19 Vaccine Trial Group†
Summary
Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK 
from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 
(AZD1222), against this variant.
Methods Volunteers (aged ≥18 years) who were enrolled in phase 2/3 vaccine efficacy studies in the UK, and who were 
randomly assigned (1:1) to receive ChAdOx1 nCoV-19 or a meningococcal conjugate control (MenACWY) vaccine, 
provided upper airway swabs on a weekly basis and also if they developed symptoms of COVID-19 disease (a cough, a 
fever of 37·8°C or higher, shortness of breath, anosmia, or ageusia). Swabs were tested by nucleic acid amplification 
test (NAAT) for SARS-CoV-2 and positive samples were sequenced through the COVID-19 Genomics UK consortium. 
Neutralising antibody responses were measured using a live-virus microneutralisation assay against the B.1.1.7 lineage 
and a canonical non-B.1.1.7 lineage (Victoria). The efficacy analysis included symptomatic COVID-19 in seronegative 
participants with a NAAT positive swab more than 14 days after a second dose of vaccine. Participants were analysed 
according to vaccine received. Vaccine efficacy was calculated as 1 − relative risk (ChAdOx1 nCoV-19 vs MenACWY 
groups) derived from a robust Poisson regression model. This study is continuing and is registered with 
ClinicalTrials.gov, NCT04400838, and ISRCTN, 15281137.
Findings Participants in efficacy cohorts were recruited between May 31 and Nov 13, 2020, and received booster doses 
between Aug 3 and Dec 30, 2020. Of 8534 participants in the primary efficacy cohort, 6636 (78%) were aged 18–55 years 
and 5065 (59%) were female. Between Oct 1, 2020, and Jan 14, 2021, 520 participants developed SARS-CoV-2 
infection. 1466 NAAT positive nose and throat swabs were collected from these participants during the trial. Of 
these, 401 swabs from 311 participants were successfully sequenced. Laboratory virus neutralisation activity by 
vaccine-induced antibodies was lower against the B.1.1.7 variant than against the Victoria lineage (geometric mean 
ratio 8·9, 95% CI 7·2–11·0). Clinical vaccine efficacy against symptomatic NAAT positive infection was 70·4% 
(95% CI 43·6–84·5) for B.1.1.7 and 81·5% (67·9–89·4) for non-B.1.1.7 lineages.
Interpretation ChAdOx1 nCoV-19 showed reduced neutralisation activity against the B.1.1.7 variant compared with a 
non-B.1.1.7 variant in vitro, but the vaccine showed efficacy against the B.1.1.7 variant of SARS-CoV-2.
Funding UK Research and Innovation, National Institute for Health Research (NIHR), Coalition for Epidemic 
Preparedness Innovations, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midlands NIHR 
Clinical Research Network, and AstraZeneca.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
The COVID-19 pandemic continues to cause considerable 
mortality, placing a substantial burden on health-care 
systems around the world and having profound social 
and economic consequences due to the measures imple-
mented to control the SARS-CoV-2 virus. A number of 
SARS-CoV-2 vaccines have shown efficacy in large-scale 
phase 3 trials.1–6 Although the vaccine platforms differ, 
most use the surface spike glycoprotein of SARS-CoV-2 as 
the key antigenic target for the generation of binding and 
neutralising antibodies and T cells, and use an antigen 
coding sequence based on the originally identified Wuhan 
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lineage virus (GenBank accession number M908947). 
Several vaccines have now been licensed for emergency 
use by individual countries and large-scale vaccination 
programmes are underway with the anticipation that 
vaccination will be a key component of future disease 
control.
While vaccine trials were underway in 2020, novel 
lineages of SARS-CoV-2 were identified globally.7–9 
Especially in populations with high levels of natural or 
vaccine-induced immunity, variants that can evade 
human immune responses are likely to arise. A novel 
SARS-CoV-2 variant, designated variant of concern 
202012/01 (also known as lineage B.1.1.7),9 was iden-
tified in Kent, UK, in late 2020, and accounted for an 
expanding proportion of cases at that time, particularly 
in the southeast and east of England.9 Whereas most 
SARS-CoV-2 lineages show few mutations, B.1.1.7 has 
accrued 23 mutations across the genome, including a 
non-synonymous mutation affecting the spike protein, 
N501Y (Asn501Tyr), which might increase ACE2 receptor 
binding affinity,10 the spike deletion 69–70del associated 
with viral escape in immuno compromised individuals,9 
and the non-synonymous mutation P681H (Pro681His) 
affecting the furin cleavage site between the S1 and 
S2 subunits of spike protein, associated with in-vitro 
enhanced membrane fusion of infected cells.9,11 N501Y is 
also seen in the B.1.351 and P.1 lineages, which are also 
variants of concern.7,8
The national community testing system in the UK 
(known as Pillar 2) is delivered by a small number of 
laboratories, many of which are using a ThermoFisher 
TaqPath three-gene nucleic acid amplifi cation test 
(NAAT). 69–70del causes a loss of two amino acids at 
positions 69 and 70 and thereby causes a reproducible 
S gene dropout in this assay, referred to as S gene target 
failure (SGTF).12 Although other variants circulating in 
the UK contain this mutation, since Nov 30, 2020, 95% of 
all UK Pillar 2 69–70del sequences were due to the 
B.1.1.7 lineage,13 permitting the use of the SGTF result as 
a proxy marker for this variant between Nov 30, 2020, and 
Jan 15, 2021.14,15 Associations between SGTF (or mutations 
present in B.1.1.7) and higher viral loads16,17 and increased 
risk of transmission14 have already been shown. The 
B.1.1.7 lineage could result in an additive increase in the 
basic reproductive number (R0) of between 0·4 and 
0·7 compared with non-B.1.1.7 lineages14,18 in the current 
UK context, although the mechanisms for increased 
transmission are complex. Importantly, UK public health 
measures in place to control the virus failed to control 
spread of SGTF-containing lineages but were effective for 
those lineages without SGTF.14 Several unpublished, 
independent analyses suggest that infections associated 
with SGTF on PCR from upper respiratory samples 
might be associated with an increased fatality rate 
compared with non-SFTF-associated infections.13,19
The emergence of a variant with multiple mutations 
also raises concerns regarding the efficacy of natural 
infection-derived immunity to prevent reinfection, as 
well as regarding vaccine efficacy. Assessing immune 
evasion by B.1.1.7 in vivo is challenging given the timing 
of the emergence of this variant (approximately 8 months 
after the first wave of infections in the UK) combined 
with the finding in health-care workers that after primary 
infection, the observed median protective effect was at 
Research in context
Evidence before this study
We searched PubMed for research articles published from 
database inception until Feb 1, 2021, with no language 
restrictions, using the terms “SARS-CoV-2” AND “B.1.1.7” OR 
“VUI-202012/01” OR “VOC-202012/01” OR “Kent”. At the time 
of the search, no peer-reviewed publications were available on 
the efficacy of sera from vaccinees to neutralise B.1.1.7 lineage 
viruses. Preprint articles using convalescent sera suggest that 
neutralisation activity against pseudovirus expressing 
B.1.1.7 spike protein could be reduced compared with activity 
against pseudovirus expressing wild-type spike protein. 
Preliminary data using sera of vaccinees who were immunised 
with mRNA vaccines (Pfizer–BioNTech or Moderna) and protein 
vaccines (Novavax) found either no or a modest reduction in 
neutralisation activity against pseudoviruses with either spike 
protein with individual mutations found in B.1.1.7 or whole 
B.1.1.7 spike protein containing all lineage-defining mutations. 
Several vaccine developers have published peer-reviewed 
interim efficacy results against symptomatic COVID-19 disease, 
and others have reported preliminary efficacy results in press 
releases. At the time of searching, no peer-reviewed 
publications were available on the efficacy of a SARS-CoV-2 
vaccine against the lineage B.1.1.7. However, a Novavax press 
release suggests an adjuvanted protein vaccine has vaccine 
efficacy of 85·6% against the UK B.1.1.7 lineage in a post-hoc 
analysis.
Added value of this study
These are the first published data on the clinical efficacy of a 
vaccine against the novel B.1.1.7 variant and non-B.1.1.7 
lineages of SARS-CoV-2. ChAdOx1 nCoV-19 was efficacious 
against both the B.1.1.7 variant and non-B.1.1.7 variants. 
Furthermore, vaccination reduced viral load and length of 
NAAT positivity against both B.1.1.7 and non-B.1.1.7 lineages.
Implications of all the available evidence
The ChAdOx1 nCoV-19 vaccine has been given emergency use 
authorisation in multiple countries, including the UK. 
The B.1.1.7 variant is currently responsible for the majority of 
COVID-19 disease in the UK. These findings support the 
ongoing use of ChAdOx1 nCoV-19 in mass vaccination 
programmes to both prevent symptomatic B.1.1.7 disease and 
reduce the opportunity for viral transmission.
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least 5 months.20 However, reinfection with B.1.1.7 and 
subsequent critical illness has been reported.21
Amino acid 501 of the SARS-CoV-2 spike protein 
sits within the receptor binding domain (RBD) of the 
S1 subunit. The RBD binds to ACE2 receptors and permits 
viral entry into host cells and is a key target for neutralising 
antibodies. Neutralising antibodies outcompete binding to 
the RBD, thereby preventing infection from both pseudo-
virus and wild-type virus.22 Early in-silico analysis suggests 
that the mutations present in B.1.1.7 might confer only 
small changes in epitope signal.23 Early studies assessing 
the neutralising ability of sera from convalescent patients 
and vaccinees against pseudoviruses expressing some 
mutations present in B.1.1.7 or the entire B.1.1.7 spike 
protein suggest no or little reduction in neutralisation 
compared with older circulating viral variants.24–28 Early 
reports suggest that vaccine efficacy might not be reduced 
against this variant.4
The B.1.1.7 variant in the UK arose while there was a 
low level of population immunity from natural infection 
and before vaccine programmes had begun, so the 
variant is likely to have been selected for improved ACE2 
receptor binding and transmissibility, rather than as 
a result of vaccine-induced immunity. Furthermore, 
multiple epitopes are recognised by neutralising antibody 
and other antibody functions29 and binding might occur 
at non-RBD epitopes in the spike protein, which could 
provide protection even with the presence of the 
mutations recognised in B.1.1.7. T-cell responses could 
also provide protection against infection and have been 
shown after vaccination with the mRNA30,31 and viral 
vector vaccines32 that are currently available in the UK.
Previously, we reported the efficacy of the simian 
adenoviral vectored vaccine ChAdOx1 nCoV-19 (AZD1222) 
in randomised controlled trials in Brazil and the UK,3 in 
analyses done before the spread of the B.1.1.7 variant 
across the UK. In this study, we provide both an in-
vitro analysis of vaccine-induced neutralising antibody 
responses against B.1.1.7 and an analysis of the clinical 
efficacy of ChAdOx1 nCoV-19 against disease caused by 
the B.1.1.7 variant of concern, using data from the UK. As 
novel variants are identified, new targeted vaccines might 
be needed in future public health programmes as booster 
doses. We also present data on the immune response to 
ChAdOx1 nCoV-19 in people who previously received 
other ChAdOx1-vectored vaccines.
Methods
Study design and participants
COV002 is a single-blind, multicentre, randomised 
phase 2/3 trial assessing the safety and efficacy of 
the ChAdOx1 nCoV-19 vaccine. Safety, immunogenicity, 
and efficacy data, including the full protocol and 
statistical analysis plan have been previously published 
in detail.3,29,33,34
For the current analysis, only participants in efficacy 
cohorts (n=8534) were included. Briefly, these were adults 
aged 18 years and older, enrolled at 19 study sites in 
England, Wales, and Scotland. Enrolment targeted partici-
pants in occupations with potentially high SARS-CoV-2 
exposure, such as those in health and social care set-
tings. Participants were randomly assigned in a 1:1 ratio 
to receive standard-dose ChAdOx1 nCoV-19 vaccine 
(5 × 10¹⁰ viral particles) or a meningococcal group A, C, W, 
and Y conjugate vaccine (MenACWY) as control. A subset 
of participants (n=2773) received a low-dose vaccine 
(2·2 × 10¹⁰ viral particles) as their first dose or control, as 
previously described.3
This study was approved in the UK by the Medicines and 
Healthcare products Regulatory Agency (MHRA), reference 
21584/0428/001–0001, and the South-Central Berkshire 
Research Ethics Committee, reference 20/SC/0179.
Procedures
Participants were reminded weekly by email or text 
message to contact the trial team if they developed 
COVID-19 symptoms, including at least one of cough, a 
fever of 37·8°C or higher, shortness of breath, anosmia, or 
ageusia. Participants who met criteria for symptomatic 
testing underwent clinical assessment and nasopha-
ryngeal and oral swabbing at their local clinical site. 
Samples were processed using MHRA-derogated NAAT 
assays within National Health Service (NHS) diagnostic 
laboratories accredited by the UK Accreditation Service for 
each study site.
Additionally, participants were asked to provide weekly 
self-collected nose and throat swabs for NAAT testing from 
1 week after first vaccination using home test kits provided 
by the Department of Health and Social Care. Symptoms 
in these participants were not routinely assessed because 
swabs were done at home and sent for testing by 
mail. Home testing kits were processed at laboratories 
designated by the Department of Health and Social Care. 
The Glasgow, Milton Keynes, and Alderley Park Lighthouse 
Laboratories processed the majority of swab samples from 
weekly home test kits (98·3% to Jan 14, 2021) and 
exclusively used the ThermoFisher TaqPath assay (Thermo 
Fisher Scientific, Waltham, MA, USA; target genes ORF1ab, 
S, and N) for viral detection. Participants were directly 
informed of their results by text and email from the NHS. 
Results from trial-barcoded swabs were provided to the 
trial team by NHS Digital. Safety data were reviewed 
regularly by an independent data safety monitoring board.
For immunogenicity assays, sera from vaccinated 
participants were tested using a live SARS-CoV-2 
microneutralisation assay (evaluating ND50, the titre at 
which 50% virus neutralisation is achieved), at Public 
Health England (Porton Down, UK), as described pre-
viously.33 The B.1.1.7 lineage and a canonical non-B.1.1.7 
Victoria lineage (BetaCoV/Australia/VIC01/2020) were 
used in neutralising assays.
Humoral responses at baseline and after vaccination 
in recipients of a different previous ChAdOx1 vaccine 
were assessed using a standardised total IgG ELISA 
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against trimeric SARS-CoV-2 spike protein, as previously 
described.33
SARS-CoV-2 RNA from trial participant home test kits 
and diagnostic swabs was identified at Lighthouse 
Laboratories and 15 of 19 study site laboratories. Samples 
were batched at the point of testing, and consolidated 
batches were sent for sequencing and genome assembly 
to COVID-19 Genomics UK partner laboratories. The 
majority of sequences (73%) during the study period 
were generated by Oxford Viromics (Wellcome Centre 
for Human Genetics, University of Oxford, Oxford, UK) 
using the quantitative veSEQ approach.35,36 Controls were 
checked to ensure no evidence of amplification in the 
negative tests and that expected RNA quantification was 
consistent with cycle threshold (Ct) values provided by 
the testing laboratories. All samples were processed by 
laboratory staff who were masked to vaccine allocation.
Viral genomes were assembled as previously 
described,35 and variant frequencies were computed 
using shiver (tools/AnalysePileup.py),37 with the default 
settings of no base alignment quality and maximum 
pileup depth of 1 000 000. Lineages were assigned by 
Pangolin version 2.1.7 (lineages version 2021–02–12) 
using the determined consensus genome for each 
sequenced sample. If the proportion of gaps was greater 
than 50% (the recommended minimum for Pangolin), 
lineages were assigned on the basis of presence of 
lineage-defining mutations in the spike gene.9 Samples 
that could not be assigned a lineage by either method 
were classified as unknown. Consensus sequences 
were aligned using MAFFT version 7.402.38 Phylogenetic 
reconstruction was per formed on the align ment 
con sisting of consensus sequences rooted with the 
Wuhan-Hu-1 reference sequence (RefSeq NC_045512), 
using IQ-TREE version 1.6.12,39 with the generalised time 
reversible + FreeRate model and 1000 bootstrap replicates.
Outcomes
The primary outcome was symptomatic COVID-19 
disease, defined as a positive NAAT result on an upper 
airway swab in a participant with at least one symptom, 
including cough, fever of 37·8°C or higher, shortness of 
breath, anosmia, or ageusia.
Asymptomatic infections and those with unknown 
symptoms detected through weekly swabbing were a 
secondary outcome. Any NAAT postive infection was 
a secondary outcome and consisted of primary symp-
tomatic cases, non-primary symptomatic cases (those 
with other symptoms such as nausea or diarrhoea), 
asymptomatic cases, and cases for which symptoms were 
unknown. Additional exploratory outcomes included 
Ct values from NAATs as an inverse proxy for viral load, 
and the number of weeks positive on any NAAT.
Statistical analysis
Cases were included in efficacy analyses from randomised 
participants enrolled in phase 3 efficacy cohorts that 
occurred between Oct 1, 2020, and Jan 14, 2021. Partici-
pants were analysed according to vaccine received. Both 
those receiving two standard doses (SD/SD group), or a 
low dose followed by a standard dose (LD/SD group) are 
included. Single-dose recipients were excluded. Cases 
were excluded if they occurred fewer than 15 days after 
the second dose of vaccine or occurred in participants 
who were not seronegative on a SARS-CoV-2 N protein 
assay at baseline.
The ChAdOx1 nCoV-19 vaccine was licensed for use in 
the UK on Dec 30, 2020, with priority groups for vaccine 
roll-out (ie, older adults and front-line health-care 
workers) identified to prevent mortality and support the 
NHS and social care system. The majority of participants 
in the trial were recruited from these high-exposure 
populations and were therefore eligible for vaccination 
under the government NHS coronavirus vaccine 
programme. Participants who were unblinded in order to 
receive a vaccine through the government COVID-19 
vaccination scheme were included in the analysis up 
until the day of their unblinding, and any cases after that 
were not included in this analysis. All endpoints were 
reviewed for inclusion by an independent, blinded 
adjudication committee.
Vaccine efficacy was calculated as 1 – relative risk 
(ChAdOx1 nCoV-19 vs MenACWY groups) calculated 
from a robust Poisson model in SAS version 9.4. The 
model contained terms for treatment group and vaccine 
group (LD/SD or SD/SD). The logarithm of the period at 
risk was used as an offset variable in the model to adjust 
for volunteers having different follow-up times during 
which the events occurred. The code for model fitting is 
provided in the appendix (p 12).
To determine whether vaccination with ChAdOx1 
nCoV-19 was associated with reduced viral load, NAAT Ct 
values, as a proxy for viral load, were analysed from 
weekly swabs from home test kits processed in 
Lighthouse Laboratories. Ct values for swabs done at 
symptomatic visits were not available. The minimum Ct 
value across the N and ORF1ab genes from each NAAT 
was computed for each swab and the minimum Ct value 
across all positive swabs for each participant was 
compared between vaccine groups using a Wilcoxon 
rank sum test. To determine whether vaccination was 
associated with a reduced number of weeks of NAAT 
positivity, the number of weeks from the first 
NAAT positive swab until the last NAAT positive swab 
during the NAAT-positive period was calculated. Three 
consecutive NAAT negative swabs were considered to 
indicate the end of the NAAT-positive period. The 
number of weeks positive was compared between vaccine 
groups using a Wilcoxon rank sum test.
Neutralising titres from a live-virus microneutralisation 
assay were available from sera tested against both 
the B.1.1.7 lineage and the Victoria lineage. Data were 
log2-transformed to achieve a normal distribution and 
the geometric mean ratio (Victoria/B.1.1.7) was computed 
For Pangolin software see 
https://pangolin.cog-uk.io
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to show the change in neutralising potential, and 
log2 titres were compared using a paired t test.
Anti-SARS-CoV-2 spike IgG antibody titres (tested by 
ELISA) in individuals who had received a previous 
different ChAdOx1 vaccine were compared with those 
who received two standard doses of ChAdOx1 nCoV-19 at 
14 and 28 days after the first dose, and 28 days after the 
second dose using Wilcoxon rank sum test.
Baseline characteristics were compared between 
individuals with B.1.1.7 versus non-B.1.1.7 variants using 
χ² and Fisher’s exact tests for binary variables, a Wilcoxon 
rank sum test for body-mass index, and Cochran-
Armitage tests for ordinal age groups and prime-boost 
intervals.
This study is registered with ClinicalTrials.gov, 
NCT04400838, and ISRCTN, 15281137.
Role of the funding source
AstraZeneca reviewed the data from the study and the 
final manuscript before submission, but the academic 
authors retained editorial control. All other funders of 
the study had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
report.
Results
Participants in efficacy cohorts were recruited between 
May 31 and Nov 13, 2020, and received booster doses 
between Aug 3 and Dec 30, 2020. Of 8534 participants 
in the primary efficacy cohort, 6636 (78%) were aged 
18–55 years, 5065 (59%) were female, and 7863 (92%) 
were White. 5623 (66%) participants worked in a health 
or social care setting (appendix p 2).
Between Oct 1, 2020, and Jan 14, 2021, 520 participants 
developed SARS-CoV-2 infection. 1466 NAAT positive 
nose and throat swabs were collected from these 
participants during the trial. Sequences were available 
from 401 of these swabs, representing 311 cases. 219 of 
these cases occurred in participants in the primary 
efficacy cohort and before unblinding, of which 147 were 
cases of primary symptomatic COVID-19 and 53 were 
asymptomatic or had unknown symptoms (figure 1).
For primary symptomatic cases for which sequence 
data were available, 52 (35%) of 147 were due to the B.1.1.7 
variant and 95 (65%) were caused by non-B.1.1.7 lineages. 
Asymptomatic infections or those with unknown symp-
toms were similarly distributed, with 19 (36%) of 
53 infections due to the B.1.1.7 variant and 34 (64%) due 
to non-B.1.1.7 lineages. The majority of cases of non-B.1.1.7 
Figure 1: Flow diagram of swabs included in the analysis
1466 samples from participants who first tested 
positive between Oct 1, 2020, and Jan 14, 2021 
757 samples sequenced
401 samples with lineage determined (311 cases)
709 samples not sequenced or unknown if 
sequenced
334 no result from sequencing
13 mixed or unknown result (sequence data 
suggest contamination)
9 results pending
92 cases excluded from analysis
60 not in primary efficacy cohort
32 events censored at the time of 
unmasking
219 cases available for analysis
147 primary symptomatic cases
53 asymptomatic or unknown cases
19 non-primary symptomatic cases
Figure 2: Consensus phylogeny of SARS-CoV-2 genomes identified in this study
Clades are coloured by variant lineage and tips are coloured by vaccine allocation. Only genomes with at least 
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lineage were caused by B.1.177 (figure 2). Cases of B.1.1.7 
first arose in late November, 2020, in trial sites in London 
and formed an increasing proportion of positive swabs 
during December, 2020, and January, 2021 (figure 3).
Vaccine efficacy of ChAdOx1 nCoV-19 was 70·4% 
(95% CI 43·6 to 84·5) against symptomatic COVID-19 
caused by the B.1.1.7 variant and 81·5% (67·9 to 89·4) 
against symptomatic COVID-19 caused by non-B.1.1.7 
variants. For cases of asymptomatic or unknown symp-
tom infection obtained from weekly self-swabs, vaccine 
efficacy was higher for non-B.1.1.7 infections (69·7%, 
33·0 to 86·3) than for B.1.1.7 (28·9%, –77·1 to 71·4), 
although fewer cases were available for analysis, so CIs 
are wide and overlapping. In contrast, no efficacy was 
seen for asymptomatic or unknown infec tions that were 
not sequenced (5·6%, –42·3 to 37·3) or for which no 
sequence result was obtained (–27·0%, –108·1 to 22·5). 
Overall efficacy from all cases was 61·7% (36·7 to 76·9) 
against the B.1.1.7 variant and 77·3% (65·4 to 85·0) 
against other variants (table). Baseline demographics in 
individuals with the B.1.1.7 variant were similar to those 
with non-B.1.1.7 variants, as were their prime-boost 
intervals (appendix pp 2–4).
36 (69%) of 52 cases of primary symptomatic COVID-19 
caused by the B.1.1.7 variant occurred in participants 
who received SD/SD vaccines, and 16 (31%) occurred in 
participants who received LD/SD vaccines. Non-B.1.1.7 
variant cases of primary symptomatic COVID-19 were 
similarly distributed with 61 (64%) of 95 in the SD/SD 
group and 34 (36%) in the LD/SD group. Vaccine efficacy 
against the B.1.1.7 variant was 66·7% (95% CI 29·2–84·3) 
in the SD/SD group and 77·9% (22·5–93·7) in the 
LD/SD group. For non-B.1.1.7 variant cases, vaccine 
efficacy was 78·0% (57·7–88·5) in the SD/SD group 
compared with 87·2% (63·7–95·5) in the LD/SD group. 
When stratified by SD/SD or LD/SD group, few cases 
were available for robust comparisons for asymptomatic 
or unknown infections (appendix p 5).
No participants from the cohorts in this study were 
hospitalised or died due to COVID-19 disease.
Minimum Ct values (an inverse proxy for peak viral 
load) from Lighthouse Laboratory swabs in participants 
who received ChAdOx1 nCoV-19 (median 28·8, 
IQR 20·5–33·5) were higher than in those who received 
the control vaccine (20·2, 15·5–29·6, p<0·0001; appendix 
p 6) and participants were NAAT positive for a shorter 
period of time (p<0·0001; appendix p 7). Primary 
symptomatic cases had lower Ct values than asymp-
tomatic or unknown symptom cases (median 18·2 
[15·0–25·0] vs 29·7 [21·6–33·5], primary vs asymptomatic, 
p<0·0001; figure 4) and were NAAT positive for a longer 
period of time (p<0·0001; figure 5). Almost all (169 [81%] 
of 209) asymptomatic participants returned only one 
positive swab. However, primary symptomatic cases 
remained NAAT positive for longer, with only 56 (21%) 
of 269 returning only one positive swab. Primary 









vaccine efficacy (95% CI)
Primary symptomatic COVID-19
B.1.1.7 52 (19%) 12 40 70·4% (43·6 to 84·5)
Other variants 95 (35%) 15 80 81·5% (67·9 to 89·4)
No sequence result† 30 (11%) 5 25 80·2% (48·3 to 92·4)
Not sequenced‡ 92 (34%) 27 65 59·1% (36·0 to 73·9)
Total cases 269 59 210 72·3% (63·1 to 79·3)
Asymptomatic or unknown infection
B.1.1.7 19 (9%) 8 11 28·9% (–77·1 to 71·4)
Other variants 34 (16%) 8 26 69·7% (33·0 to 86·3)
No sequence result† 64 (31%) 36 28 –27·0% (–108·1 to 22·5)
Not sequenced‡ 92 (44%) 45 47 5·6% (–42·3 to 37·3)
Total cases 209 97 112 14·6% (–12·1 to 34·9)
Any NAAT positive infection§
B.1.1.7 75 (14%) 21 54 61·7% (36·7 to 76·9)
Other variants 144 (28%) 27 117 77·3% (65·4 to 85·0)
No sequence result† 101 (19%) 44 57 23·7% (–13·0 to 48·5)
Not sequenced‡ 200 (38%) 81 119 32·9% (11·0 to 49·5)
Total cases 520 173 347 50·9% (41·0 to 59·0)
Data include SD/SD and LD/SD seronegative efficacy cohorts only. NAAT=nucleic acid amplification test. SD=standard 
dose. LD=low dose. *Data in this column are n (%) or n. †No viable sequence obtained or unprocessed due to cycle 
threshold >30. ‡Sample did not enter sequencing pipeline, was destroyed, or sequencing results are yet to be obtained. 
§Includes primary symptomatic cases, non-primary symptomatic cases (those with other symptoms such as nausea or 
diarrhoea; not shown separately), asymptomatic cases, and cases for which symptoms were unknown.
Table: Vaccine efficacy against B.1.1.7 and non-B.1.1.7 variants
Figure 3: Weekly and cumulative number of B.1.1.7 and non-B.1.1.7 isolates 
identified in the UK trial between Oct 1, 2020, and Jan 14, 2021
Bars show overall weekly case counts (left axis) and lines show cumulative case 
counts (right axis).
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had a shorter NAAT-positive period (median 1·0 week, 
IQR 1·0–2·0) than those who received the control vaccine 
(2·0 weeks, 1·0–3·0). The number of weeks positive in 
B.1.1.7 variant cases was not different to the non-B.1.1.7 
variant cases (p=0·85; appendix p 7).
In a live-virus neutralisation assay (n=49), neutralising 
titres of ChAdOx1 nCoV-19 recipient sera were nine times 
lower against the B.1.1.7 lineage than against the Victoria 
lineage (geometric mean ratio 8·9, 95% CI 7·2–11·0; 
figure 6).
Using an ELISA that detected total IgG against trimeric 
spike protein, we observed that participants who had 
previously received a different ChAdOx1 vector vaccine 
had similar anti-spike antibody titres at all timepoints 
after vaccination to ChAdOx1-naive individuals (appendix 
pp 9–10).
Discussion
Our findings show that while laboratory neutralising 
antibody titres generated by vaccination with ChAdOx1 
nCoV-19 vaccine are lower for the B.1.1.7 lineage, clinical 
vaccine efficacy against symptomatic COVID-19 was 
observed for the B.1.1.7 variant at 70·4%, with a lower 
bound of 43·6% for the 95% CI. These findings suggest 
either that lower neutralising antibody titres are suf-
ficient to provide protection or that other mechanisms of 
immunity could be responsible for protection from 
disease in vaccinated individuals. The efficacy against 
this new variant is an important finding for regions 
where B.1.1.7 is now the dominant variant and vaccine 
programmes are already underway. However, it should 
be noted that further mutations in spike protein observed 
in other novel lineages7,8 appear to be driven by escape 
of the virus from the neutralising activity of public 
antibodies,40,41 indicating that prevention of transmission 
might be temporary as the virus adapts to natural or 
vaccine-induced immunity.
Paired comparison of neutralising antibody activity of 
sera from ChAdOx1 nCoV-19 vaccinees showed reduced 
activity against the B.1.1.7 lineage compared with a 
canonical non-B.1.1.7 lineage (Victoria). The Victoria 
lineage is phylogenetically similar to the original Wuhan 
outbreak lineage and has only a single mutation in 
spike protein (S247R; Ser247Arg). Vaccine sera from the 
Pfizer–BioNTech BNT162b2 mRNA recipients showed 
no change in neutralising activity using pseudovirus 
assays comparing a vesicular stomatitis virus (VSV) 
expressing B.1.1.7 or ancestral Wuhan lineage spike 
protein.26 Sera from recipients of the Moderna 
mRNA-1273 vaccine showed similar neutralising activity 
against VSV and lentivirus pseudoviruses expressing 
full-length spike protein from either B.1.1.7 or a Wuhan 
lineage,42 and this finding was also seen in a live 
neutralisation assay.43 However, a further live coronavirus 
neutralisation assay showed that sera from BNT162b2 
and ChAdOx1 nCoV-19 vaccinees had a 2·0–3·3 times 
reduction in neutralisation activity against B.1.1.7 
compared with the Victoria lineage,44 in keeping with our 
findings. In the absence of a standardised method, these 
apparently different results with neutralising antibody 
assays using pseudoviruses and live virus highlight the 
need for caution in interpretation of viral neutralisation 
data. Further work is needed to compare in parallel sera 
from individuals immunised with different vaccines 
within the same in-vitro assay.
Despite the large reduction in measured live 
neutralising activity against B.1.1.7 virus, the vaccine 
provided strong protection against B.1.1.7 variant disease, 
with the lower bound of the 95% CI above the 
30% threshold recommended by WHO.45 In line with 
previously published data,3,46 protection was also shown 
against the non-B.1.1.7 strains, the majority of which 
were due to the B.1.177 lineage.
The number of samples available for analysis was not 
sufficient to power a study to determine whether there 
was a small difference in efficacy between the B.1.1.7 
and non-B.1.1.7 variants; therefore, we cannot rule out 
an 11% reduction in efficacy. A similar finding of a 
10% reduction in efficacy against the B.1.1.7 variant was 
reported for the adjuvanted spike protein-based vaccine, 
Novavax NVX-CoV2373, from a smaller number of 
Figure 4: Minimum Ct values across all NAAT positive swabs
Ct values from positive NAATs performed at Lighthouse Laboratories using a ThermoFisher TaqPath three-gene 
assay. Each datapoint represents one participant. For each participant, the minimum of the Ct value for the N gene 
and ORF1ab gene was taken for each NAAT positive swab, and the minimum across all swabs for the same 
participant was calculated as a proxy for maximum viral load. Low Ct values are associated with a higher viral load. 
The midlines of the boxes show medians and the outer bounds of the boxes show IQRs. Error bars show the most 
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sequences.4 This vaccine is also based on the Wu-1 
reference spike gene sequence. If these results are 
confirmed on formal analysis, they will support our 
finding that immune responses elicited by ancestral spike 
protein offer a high degree of cross-protection against the 
B.1.1.7 lineage. This suggestion is encouraging and would 
indicate that currently deployed vaccines that are also 
based on early circulating viral lineages (including mRNA 
and inactivated vaccines) are also likely to be protective 
against B.1.1.7. ChAdOx1 nCoV-19 has been deployed in 
the UK national vaccination programme since Jan 4, 2021, 
during which time B.1.1.7 has been the dominant 
circulating lineage.13 Early national vaccine effectiveness 
data has shown that a single dose of ChAdOx1 nCoV-19 
confers protection from both symptomatic disease and 
COVID-19-related hospitalisation,47 consistent with the 
findings presented here. No participants in this study had 
evidence of the novel E484K (Glu484Lys) spike mutation 
first described in the B1.351 lineage identified in South 
Africa. The E484K mutation appears to result in a lower 
neutralising ability of mRNA vaccine sera.48 Preliminary 
data suggest that, in common with other ancestral spike-
based vaccines, ChAdOx1 nCov-19 might have a lower 
clinical efficacy against upper respiratory infection caused 
by viral lineages bearing this mutation.49 Further work is 
ongoing to ascertain the impact of E484K on the 
neutralising activity and efficacy afforded by ChAdOx1 
nCov-19.
Preclinical COVID-19 vaccine studies suggest that the 
development of neutralising antibody is associated with 
protection from subsequent challenge with live virus.50 In 
the absence of a formal correlate of protection, vaccine 
developers have therefore measured neutralising anti-
body titres post vaccination as a surrogate of likely efficacy. 
Our findings that ChAdOx1 nCoV-19 offers protection 
against the B.1.1.7 lineage could mean that a lower abso-
lute level of neutralising antibody is needed to prevent 
symptomatic infection.
Different immune mechanisms could also be responsible 
for the protection afforded by ChAdOx1 nCoV-19. Antibody-
dependent complement deposition and antibody-depend-
ent natural killer cell activation are associated with 
protection from challenge in animal models.51 We have 
previously shown that ChAdOx1 nCoV-19 elicits robust 
antibody-dependent monocyte phagocytosis, antibody-
dependent neutrophil phagocytosis activity, and antibody-
dependent natural killer cell activa tion after two doses of 
vaccine,29 at similar levels to those seen in convalescent 
sera. Antibodies mediating these functions could have 
complementarity determining regions that recognise and 
bind to alternative confor mational epitopes on spike 
protein to those bound by neutralising antibodies, 
explaining the observed clinical efficacy against B.1.1.7.
T-cell responses are associated with recovery from 
clinical COVID-19 disease52 and we have previously 
reported that ChAdOx1 nCoV-19 generates spike-specific 
T cells that peak at 14 days after priming vaccination.34 
We have previously shown that the peptide pools most 
frequently recognised by vaccine-elicited T cells span 
amino acids 311–430 and 101–200 of the S1 domain, 
which are unaffected by the mutations seen in B.1.1.7. 
These findings support the suggestion that cellular 
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Figure 5: Length of the NAAT-positive period per participant
Three primary symptomatic participants who received ChAdOx1 nCoV-19 remained NAAT positive for 8, 9, and 
11 weeks, respectively, and one primary symptomatic participant who received the control vaccine remained NAAT 
positive for 11 weeks; these cases are not shown in the figure. NAAT=nucleic acid amplification test.
Figure 6: Live-virus microneutralisation antibody titres of sera against 
B.1.1.7 and a canonical non-B.1.1.7 strain (Victoria)
The geometric mean titre is 58 (95% CI 44–77) for B.1.1.7 and 517 (424–631) for 
Victoria. The geometric mean ratio (Victoria vs B.1.1.7) is 8·9 (95% CI 7·2–11·0). 
The midlines of the boxes show medians and the outer bounds of the boxes 
show IQRs. Error bars show the most extreme point within 1·5 × IQR above or 
below the 75th or 25th percentile. Lines connect samples from the same 
participant collected at the same trial timepoint (n=49). ND50=titre at which 
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immune responses to ChAdOx1 nCoV-19 are sustained 
against the new variant, independently of neutralising 
activity. Further evaluation of the cross-reactivity of 
vaccine-derived T cell clones to B.1.1.7 spike peptides is 
underway.
Vaccine efficacy against asymptomatic infection using 
sequenced swabs was high (70%) for non-B.1.1.7 variants. 
It was higher than our previously published estimate 
of 27%, which was based on NAAT positivity alone,3 
and substantially higher than the efficacy seen in the 
asymptomatic cases that have not been sequenced (6%), 
or in those for whom no result from sequencing could be 
obtained (–27%). It is possible that some of the specimens 
which could not be sequenced were false-positive samples 
generated by low-level plate contamination or amplicon 
contamination in the NAAT assay. These false positives 
would fall into the category with –27% efficacy, along with 
true-positive specimens with very low absolute viral loads 
or degraded RNA. The contrasting results for efficacy 
against asymptomatic disease when using sequencing 
as a confirmation of the presence of virus in the specimen 
are notable and point to the potential for false-positive 
NAAT results to alter efficacy estimates. In our study, 
more than 200 000 nose and throat swabs from partici-
pants self-swabbing at home have been tested by NAAT. 
The false-positive rate within Lighthouse Laboratories 
used for the community testing is unknown, although 
early estimates based on other historical RNA viral 
RT-PCR testing suggested rates of 0·8–4·0%.53 Assuming 
a low false-positive rate of 0·1%, this equates to 200 false-
positive swabs, which could skew an attempt to estimate 
vaccine efficacy. The higher estimate of efficacy against 
asymptomatic infection in this study from sequenced 
swabs is less likely to be affected by false-positive results 
and therefore might be more reliable. However, inflated 
efficacy against asymptomatic infection could also be 
caused by lower viral loads in true-positive samples from 
vaccine recipients, making sequencing more difficult for 
these samples, thereby lowering the counts in the vaccine 
group of the study and inflating vaccine efficacy for 
asymptomatic infections. This bias would be unlikely to 
affect primary symptomatic cases, for which viral loads 
are higher.
The presence of viral RNA detected by NAAT in a 
diagnostic swab might not represent transmissible live 
virus. Determining exact Ct thresholds associated with 
infectivity is complicated by different RT-PCR platforms, 
specimen types, and gene targets, but the probability of 
recovery of live virus appears reduced from samples 
with high Ct values.54–56 Previous studies have shown no 
difference in viral load between symptomatic and 
asymptomatic individuals.54,57 In our study, individuals 
who did not report symptoms had lower viral loads than 
symptomatic individuals and were NAAT positive for a 
shorter period of time. This finding is consistent with 
published data that asymptomatic individuals might be 
responsible for fewer secondary transmissions than 
symptomatic individuals.58 The viral load among those 
with a NAAT-positive swab in the ChAdOx1 nCoV-19 
vaccinated group was statistically significantly lower 
than among those who were in the control group. Taken 
with our recent analysis,46 which showed a 64% reduc-
tion in any NAAT-positive result after a single dose of 
ChAdOx1 nCoV-19, our findings suggest that even those 
vaccinees with a NAAT-positive swab could be less likely 
to transmit the virus than an unvaccinated NAAT-
positive individual. These observations provide strong 
support for mass vaccination as a tool to control 
pandemic coronavirus, when the vaccine is reasonably 
well matched to the circulating variant.
Since December, 2020, regulatory authorities around the 
world have approved emergency use of several COVID-19 
vaccines as part of the strategy to combat COVID-19 
disease. As an increasing proportion of the population is 
vaccinated, selection of mutations that allow immune 
evasion may occur, requiring revaccination with antigens 
derived from the new lineages. Concerns exist that repeated 
doses of adenoviral vaccine vectors could generate anti-
vector immunity, which could impede responses to the 
pathogen transgene. We have previously shown that anti-
ChAdOx1 vector antibodies do not affect anti-spike antibody 
responses or spike-specific T-cell responses.34 In this study, 
we showed that individuals who had received a previous 
ChAdOx1-vectored vaccine for a non-spike transgene at 
least 1 year before receipt of ChAdOx1 nCoV-19 had similar 
binding antibody responses to spike protein to ChAdOx1-
naive individuals. However, the impact on transgene 
responses of, for example, an annual vaccination with the 
same adenoviral vector remains uncertain and heter-
ologous prime-boost strategies incorporating different 
vaccine platforms might be required.
A limitation of this study is that sequences could not be 
obtained from all positive swab samples due to logistical 
constraints in laboratories processing multiple clinical 
samples during the COVID-19 pandemic. The sample size 
for this analysis was determined by sequence availability. 
However, the emergence of the B.1.1.7 variant as domi-
nant lineage within the UK coupled with the roll-out of 
the ChAdOx1 nCoV-19 vaccine justified an exploratory 
analysis. There were no cases of hospitalisa tion or death 
in these trial participants, so we cannot comment on the 
efficacy of the vaccine on these endpoints.
Although human error in the receiving and sequencing 
laboratories and missteps in quality control of data 
matching between laboratories could have affected data 
veracity, in most cases multiple swabs were obtained from 
the same individual over a period of weeks, allowing 
corroboration of in-host minor variants, and providing 
certainty of sequence linkage to a given participant. The 
sequences obtained for this study were generated by 
multiple sequencing laboratories affiliated with the 
COVID-19 Genomics UK Consortium, using local infra-
structure for library preparation and sequencing, with 
independent quality control procedures performed at each 
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sequencing site and centrally within COVID-19 Genomics 
UK. The use of heterogeneous sequencing data from high-
throughput processes war rants some caution in the 
interpretation of consensus genomes. Only genomes that 
had no evidence of contamination were included in this 
analysis, with sequences showing evidence of mixed 
variant calls at multiple lineage-defining sites being 
manually excluded. Furthermore, samples with a high 
Ct value (>30) were not routinely sequenced by several 
COVID-19 Genomics UK laboratories, thus limiting our 
ability to assess the lineage of low viral load specimens, 
which were over -represented in asymptomatic participants.
The emergence of new lineages of SARS-CoV-2 due to 
viral mutation and immune and fitness selection is 
inevitable. Here, we show that the ChAdOx1 nCoV-19 
vaccine provides protection against symptomatic disease 
caused by the novel B.1.1.7 lineage. Vaccination with 
ChAdOx1 nCoV-19 also results in a reduction in the 
duration of shedding and viral load, which might reduce 
transmission of disease, supporting the ongoing use of 
this vaccine to protect populations at risk of disease.
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